Introduction
The common cold poses significant health concerns, particularly for individuals with weakened immune systems. This study evaluates the efficacy and safety of Ganduqing granules (GG), a proprietary Chinese medicine, in treating cold symptoms among susceptible population.
Methods
Participants aged 18–70, who experienced more than four colds annually, with symptom onset within 48 hours, and who had received no prior treatment were included. They were randomly assigned to GG group or placebo group and were evaluated at baseline and follow-up. The participants and investigators were double-blinded. The primary outcome was the overall symptom recovery time. Other outcomes included individual symptom recovery, clinical remission rates, immune cell percentages, cytokine levels, and oxidative stress markers.
Results
A total of 120 participants were enroled and evenly divided into two groups. The full analysis set included 118 participants, and the per protocol set included 108 participants. The mean time to overall symptom recovery in the Ganduqing group (60 cases) was 84.93 ± 25.95 hours, and that in the placebo group (58 cases) was 96.19 ± 20.50 hours; the former was significantly shorter than the latter by 11.26 hours (95% CI: −19.69 to −2.84, P = 0.009). By day three, the GG group showed markedly higher recovery rates compared to the control group, with a relative risk of 2.11 (95% CI: 1.14–3.90). Immune cells and cytokine analyses suggested immunomodulatory effects.
Conclusions
GG effectively shortens the duration of cold symptoms, possibly by modulating the immune system and reducing inflammation.
扫码关注我们
求助内容:
应助结果提醒方式:
